Reaction

Venous Thrombosis Limb reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,067 reports · 60 co-occurring drugs

As of the last recalculation, Venous Thrombosis Limb appears in 2,067 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is FONDAPARINUX SODIUM (PRR 28.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fondaparinux Sodium	23	28.9	29.0
Granisetron Hydrochloride	23	22.4	22.5
Granisetron	16	15.5	15.5
Baricitinib	13	13.7	13.7
Dalteparin Sodium	13	12.4	12.5
Iron Sucrose	11	11.7	11.7
Heparin Sodium	15	11.1	11.1
Drospirenone And Ethinyl Estradiol	47	10.9	10.9
Cortisone Acetate	13	10.7	10.7
Romiplostim	15	10.1	10.1
Etonogestrel And Ethinyl Estradiol	21	9.6	9.6
Minocycline	11	9.5	9.6
Haloperidol	22	9.2	9.2
Terbinafine Hydrochloride	8	9.1	9.1
Haloperidol Lactate	22	9.0	9.0
Febuxostat Tablets 40 Mg	9	8.9	9.0
Febuxostat Tablets 80 Mg	9	8.9	9.0
Enoxaparin Sodium	50	8.9	8.9
Voriconazole Injection	19	8.9	8.9
Fosaprepitant Dimeglumine	11	8.1	8.1
Bevacizumab	94	8.0	8.0
Tamsulosin Hydrochloride	15	7.4	7.5
Crizotinib	9	7.2	7.2
Doxazosin Mesylate	25	7.0	7.0
Dexamethasone Sodium Phosphate	7	7.0	7.0
Raloxifene Hydrochloride	10	6.9	6.9
Voriconazole	20	6.7	6.7
Panitumumab	10	6.5	6.5
Rivaroxaban	123	6.3	6.3
Pemetrexed Disodium	23	6.1	6.1
Abemaciclib	12	6.1	6.1
Febuxostat	10	6.0	6.0
Aprepitant	11	6.0	6.0
Paclitaxel (Aibumin-Bound)	48	6.0	6.0
Paclitaxel	53	5.5	5.5
Cetuximab	16	5.2	5.2
Carboplatin	63	5.1	5.1
Osimertinib	16	5.1	5.1
Carfilzomib	14	5.0	5.0
Fluorouracil Cream, 0.5%	37	5.0	5.0
Cisplatin	37	4.8	4.8
Vincristine Sulfate	14	4.8	4.8
Ado-Trastuzumab Emtansine	4	4.8	4.8
Fluorouracil	36	4.8	4.8
Irinotecan Hydrochloride	6	4.7	4.7
Romosozumab-Aqqg	6	4.5	4.5
Gemcitabine Hydrochloride	23	4.4	4.4
Eltrombopag Olamine	10	4.4	4.4
Bortezomib	38	4.3	4.3
Polatuzumab Vedotin	4	4.1	4.1
Oxaliplatin	30	4.1	4.1
Dabigatran Etexilate	31	4.1	4.1
Dabigatran Etexilate Mesylate	29	4.1	4.1
Pemetrexed	8	3.8	3.8
Methoxy Polyethylene Glycol-Epoetin Beta	4	3.7	3.7
Ixazomib	10	3.5	3.5
Durvalumab	7	3.5	3.5
Atezolizumab	12	3.1	3.1
Fam-Trastuzumab Deruxtecan-Nxki	3	3.0	3.0
Lenalidomide	93	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.